Corporate Banner
Satellite Banner
Chemical Process Scale Up
Scientific Community
Become a Member | Sign in
Home>News>This Article

Merck to Reduce Headcount by 1,100

Published: Saturday, September 08, 2012
Last Updated: Monday, September 17, 2012
Bookmark and Share
Merck has signed an agreement with employee representatives on an efficiency plan for the company’s operations in Germany.

The efficiency measures are part of the company’s "Fit for 2018" business transformation program spanning all businesses and regions in order to secure Merck’s long-term competitiveness. Merck plans to eliminate around 1,100 of the 10,900 positions in Germany by the end of 2015. The positions will be reduced in a socially acceptable manner, mainly through voluntary-resignation and early retirement programs across all divisions and functions. As part of the agreement concerning the efficiency measures associated with the "Fit for 2018" program, Merck will refrain from forced redundancies until the end of 2017, with the exception of possible site closures and transfers that are still being assessed. 

“We have had constructive discussions with Works Council members for the past several months and are happy to say that we now have a roadmap that will position Merck Germany in such a way that the company is prepared for the challenges we will face,” said Kai Beckmann, member of the Executive Board and responsible for Human Resources. “This agreement is a positive development for Merck’s future and a clear commitment to Germany. Now, we need to consistently implement the measures and continue moving ahead with the changes in our company.”

“For the Works Council, it is particularly important that there will be no forced redundancies in Darmstadt and Gernsheim through the end of 2017 and we were largely able to avoid outsourcing of jobs,” added Works Council Chairman Heiner Wilhelm.

The efficiency measures for Germany comprise more than 100 individual initiatives spanning all businesses and functions. Among others, several support functions across the divisions, such as logistics, will be reorganized. Outsourcing functions to external providers – a measure that had been considered – are not planned. The only exception are activities that are already partially being outsourced to third-party suppliers, such as routine jobs connected to the approval of drugs (Regulatory Affairs), or jobs that require considerable manual labor, such as certain blending and filling activities in production. This will affect around 100 jobs. These outsourcing plans are in line with Merck’s strategic approach as set out by the “Fit for 2018” program, which calls for production to be focused on core activities that generate high value.

In the area of financial services, specifically Merck Shared Services Europe GmbH (MSSE), it has been agreed to jointly leverage efficiencies. Merck will refrain from relocating MSSE abroad, a move that had been under review in recent months, at least until the end of 2015. The parties are confident that the defined targets can also be reached at the Darmstadt location.

The production of industrial salts in Lehrte, Germany, as well as the filling operations in Hohenbrunn, Germany, will be discontinued. A total of approximately 140 employees are working at the two sites. In the months ahead, the Works Council and Merck will consider various scenarios for the two sites.

Further cost savings will be realized by a reduction in personnel costs as the result of a restructuring of the compensation system. To strengthen the Darmstadt site within the framework of the “Fit for 2018” program, Merck also plans to invest a total of at least € 250 million at this location and other sites within Germany during the next two years. The Darmstadt site, as the global headquarters of the Merck Group, will be expanded further and, as a state-of-the-art production and research center, will be able to meet the highest competitive demands. A modern and up-to-date working environment, flexible organizational structures, and suitable workspaces in research and development should be able to drive innovation, retain talents and attract skilled professionals. Darmstadt is to be expanded to become an R&D center of excellence, with a tightly networked research and knowledge platform for both pharmaceuticals and chemicals.

Merck announced its global efficiency program, which spans all regions and businesses, at the end of February. The company has already begun implementation of some efficiency programs outside Germany in recent months. For example, Merck announced in April that the headquarters of its pharmaceutical division (Merck Serono) would be moved from Geneva to Darmstadt. 

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 4,000+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Merck to Acquire Idenix
Acquisition expands portfolio of promising investigational therapies for Hepatitis C.
Tuesday, June 10, 2014
Merck Serono and Flamel to Collaborate on an Extended Release Formulation for Therapeutic Proteins
Flamel's Medusa® technology designed to allow less frequent administration of therapeutic proteins and peptides.
Wednesday, December 26, 2007
Symyx Technologies Announces Discovery Tools Agreements with Merck

Tuesday, April 22, 2003
Scientific News
Solvent-free, Catalyst-free Peracetylation of Natural Products
In this study, a tunable microwave-assisted method for the solvent-free and catalyst-free peracetylation of natural products was developed.
Sonochemical Reactors
A critical analysis of the underlying mechanisms for intensification, available reactor configurations and overview of the different applications exploited successfully are presented.
Economical and Scalable Synthesis of 6-amino-2-cyanobenzothiazole
An economical and scalable synthesis of ACBT is presented, along with advantages for scale-up over previously reported routes.
Peer Review is in Crisis, But Should be Fixed, Not Abolished
After the time to get the science done, peer review has become the slowest step in the process of sharing studies, and some scientists have had enough.
3D-Printing in Science: Conference Co-Staged with LABVOLUTION
LABVOLUTION 2017 will have an added highlight of a simultaneous conference, "3D-Printing in Science".
Cutting the Cost of Drug-Building Chemicals
EPFL scientists have developed a method to produce aryl-containing amines in a cheap and easily scalable way.
How Cloud Connectivity Can Combat the Reproducibility Crisis
This infographic explains the reproducibility crisis, and how cloud connectivity can help overcome this problem.
Porphyrins as Catalysts in Scalable Organic Reactions
This review covers the most relevant scalable porphyrin-catalysed procedures, showing how these compounds represent broad applications in chemistry.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Injecting New Life into Old Antibiotics
A new fully synthetic way to make a class of antibiotics called macrolides from simple building blocks is set to open up a new front in the fight against antimicrobial drug resistance.

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
4,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos